This protocol addresses adults aged 18 years or older with localized plaque psoriasis involving less than 10% of body surface area whose disease has not responded adequately to a prior course of targeted UVB phototherapy.
The preceding treatment line used targeted UVB phototherapy — including excimer laser (308 nm), excimer light (308 nm), or targeted NB-UVB light (311–313 nm), or alternatively topical PUVA — and did not reach the defined success threshold of PASI 75 (a 75% improvement in Psoriasis Area and Severity Index score). Failure to achieve this target is the trigger for the current protocol.
The next-line regimen for this scenario involves excimer laser (308 nm) in combination with a topical agent — the complete sequencing, selection criteria, and clinical specifics are available in the full structured protocol.
DOI: 10.1016/j.jaad.2019.04.042
Targeted UVB phototherapy, including excimer laser (308 nm), excimer light (308 nm), and targeted NB-UVB light (311-313 nm), is recommended for use in adults with localized plaque psoriasis (<10% BSA), for individual lesions, or in patients with more extensive disease.
Excimer laser (308 nm) may be combined with topical corticosteroids in the treatment of plaque psoriasis in adults.
View source ↗